-
公开(公告)号:US5492919A
公开(公告)日:1996-02-20
申请号:US190135
申请日:1994-07-06
申请人: Gareth J. Sanger , Francis D. King , Gordon S. Baxter , Laramie M. Gaster , Alberto J. Kaumann , Guy A. Kennett , Keith R. Mulholland , Mythily Vimal , Kay A. Wardle , Paul A. Wyman , Rodney C. Young
发明人: Gareth J. Sanger , Francis D. King , Gordon S. Baxter , Laramie M. Gaster , Alberto J. Kaumann , Guy A. Kennett , Keith R. Mulholland , Mythily Vimal , Kay A. Wardle , Paul A. Wyman , Rodney C. Young
IPC分类号: A61K31/41 , A61K31/42 , A61K31/435 , A61K31/445 , A61K31/54 , A61K31/55 , A61P9/00 , A61P25/00 , A61P25/04 , A61P25/20 , A61P43/00 , C07D271/06 , C07D401/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D455/02 , C07D471/04
CPC分类号: C07D271/06 , A61K31/41 , A61K31/42 , A61K31/435 , A61K31/445 , A61K31/54 , A61K31/55 , C07D401/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D455/02 , C07D471/04
摘要: The invention provides the use of a compound of formula (I) ##STR1## wherein A, E, F, U, X, Y, Z, are as defined in the specification, or a pharmaceutically acceptable salt thereof, for the treatment of diarrhea predominant irritable bowel syndrome.
摘要翻译: PCT No.PCT / GB92 / 01419 Sec。 371日期:1994年7月6日 102(e)日期1994年7月6日PCT提交1992年7月31日PCT公布。 出版物WO93 / 02677 日本公开1 9 9 3年2月18日。本发明提供式(I)化合物其中A,E,F,U,X,Y,Z如说明书中所定义,或 其药学上可接受的盐,用于治疗腹泻主要肠易激综合征。
-
公开(公告)号:US5063231A
公开(公告)日:1991-11-05
申请号:US520108
申请日:1990-05-07
申请人: Gareth J. Sanger , Helen E. Marr
发明人: Gareth J. Sanger , Helen E. Marr
IPC分类号: C07D209/52 , A61K31/40 , A61K31/403 , A61K31/435 , A61K31/445 , A61K31/46 , A61K31/55 , A61P1/00 , A61P25/04 , C07D451/06 , C07D451/14 , C07D453/02 , C07D453/06 , A61K31/44
CPC分类号: A61K31/46 , A61K31/435 , A61K31/445 , A61K31/55
摘要: A method of treatment of visceral pain in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:X--CO--Y--Z (I)whereinX is a group of formula (a), (b), (c), (d) or (e): ##STR1## wherein R.sub.a to R.sub.d are selected from hydrogen, halogen or hydroxy;R.sub.1 is hydrogen and R.sub.2 is hydrogen or C.sub.1-4 alkyl; orR.sub.1 and R.sub.2 together are a bond;R.sub.3 to R.sub.7 are independently hydrogen or C.sub.1-6 alkyl; andR.sub.4 together with R.sub.2 may be C.sub.2-7 polymethylene when R.sub.1 is hydrogen; either R.sub.8 is C.sub.1-6 alkoxy;R.sub.9 is hydrogen;R.sub.10 is amino or C.sub.1-7 alkanoylamino; andR.sub.11 is halo or C.sub.1-6 alkylthio; orR.sub.8 is hydrogen;R.sub.9 is halo, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;R.sub.10 is hydrogen or C.sub.1-6 alkoxy; andR.sub.11 is halo, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;L is CH or N;Y is NH or O, with the proviso that Y is NH when X is (e) and R.sub.8 is C.sub.1-6 alkoxy;Z is a group of formula (f), (g) or (h): ##STR2## wherein n is 2 or 3;p and q are independently 1 to 3; andR.sub.12 or R.sub.13 is methyl or ethyl.
-
公开(公告)号:US4942160A
公开(公告)日:1990-07-17
申请号:US348051
申请日:1989-05-05
申请人: Gareth J. Sanger , Helen E. Marr
发明人: Gareth J. Sanger , Helen E. Marr
IPC分类号: C07D209/52 , A61K31/40 , A61K31/403 , A61K31/435 , A61K31/445 , A61K31/46 , A61K31/55 , A61P1/00 , A61P25/04 , C07D451/06 , C07D451/14 , C07D453/02 , C07D453/06
CPC分类号: A61K31/46 , A61K31/435 , A61K31/445 , A61K31/55
摘要: A method of treatment of visceral pain in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:X--CO--Y--Z (I)whereinX is a group of formula (a), (b), (c), (d) or (e): ##STR1## wherein R.sub.a to R.sub.d are selected from hydrogen, halogen or hydroxy;R.sub.1 is hydrogen and R.sub.2 is a hydrogen or C.sub.1-4 alkyl; orR.sub.1 and R.sub.2 together are a bond;R.sub.3 to R.sub.7 are independently hydrogen or C.sub.1-6 alkyl; andR.sub.4 together with R.sub.2 may be C.sub.2-7 polymethylene when R.sub.1 is hydrogen;either R.sub.8 is C.sub.1-6 alkoxy;R.sub.9 is hydrogen;R.sub.10 is amino or C.sub.1-7 alkanoylamino; andR.sub.11 is halo or C.sub.1-6 alkylthio; orR.sub.8 is hydrogen;R.sub.9 is halo, or C.sub.1-6 alkoxy or C.sub.1-6 alkyl;R.sub.10 is hydrogen or C.sub.1-6 alkoxy; andR.sub.11 is halo, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;L is CH or N;Y is NH or O, with the proviso that Y is NH when X is (e) and R.sub.8 is C.sub.1-6 alkoxy;Z is a group of formula (f), (g) or (h): ##STR2## wherein n is 2 or 3;p and q are independently 1 to 3; andR.sub.12 or R.sub.13 is methyl or ethyl.
-
公开(公告)号:US4721720A
公开(公告)日:1988-01-26
申请号:US838904
申请日:1986-03-12
申请人: Gordon Wootton , Gareth J. Sanger
发明人: Gordon Wootton , Gareth J. Sanger
IPC分类号: C07D403/06 , A61K31/40 , A61K31/403 , A61K31/405 , A61K31/415 , A61K31/435 , A61K31/46 , A61K31/55 , A61P1/00 , A61P1/08 , A61P11/00 , A61P25/20 , A61P35/00 , C07D209/52 , C07D451/04 , C07D451/12 , C07D453/02 , C07D453/06 , A61K31/44
CPC分类号: A61K31/435 , A61K31/40 , A61K31/405 , A61K31/415 , A61K31/46
摘要: A method of treatment of emesis, anxiety and/or IBS in mammals, including humans, which method comprises administering an effective amount of a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof:Ar--Co--Y--Z (I)wherein Ar is a group of formula (a): ##STR1## wherein: R.sub.1 and R.sub.2 are independently selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl groups, thiol, C.sub.1-4 alkylthio; X is CH.sub.2, NR.sub.3, --O-- or --S-- wherein R.sub.3 is hydrogen, C.sub.1-4 alkyl, C.sub.3-5 alkenyl, phenyl or phenyl C.sub.1-4 alkyl; or Ar is a group of formula (b): ##STR2## wherein R.sub.4 to R.sub.7 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl, by C.sub.1-4 alkanoylamino or pyrrolyl, one of R.sub.4 to R.sub.7 being other than hydrogen;Y is --O-- or --NH--; andZ is a group of formula (c), (d) or (e): ##STR3## wherein n is 2, 3 or 4;R.sub.8 is hydrogen, C.sub.1-7 alkyl, C.sub.3-5 alkenyl or phenyl C.sub.1-4 alkyl optionally substituted by one or two halogen, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; ##STR4## wherein: p is 1, 2 or 3; andR.sub.9 is as defined above for R.sub.8 ;and with the proviso that, when Ar is of formula (b) and Y is --NH--, Z is a group of formula (d) or (e); ##STR5## wherein R.sub.10 is hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl-C.sub.1-3 alkyl; andone of the groups represented by R.sub.11, R.sub.12 and R.sub.13 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl and each of the other groups, which may be the same or different, is hydrogen or C.sub.1-6 alkyl.
-
公开(公告)号:US4851407A
公开(公告)日:1989-07-25
申请号:US245892
申请日:1988-09-16
申请人: Gordon Wootton , Gareth J. Sanger
发明人: Gordon Wootton , Gareth J. Sanger
IPC分类号: C07D403/06 , A61K31/40 , A61K31/403 , A61K31/405 , A61K31/415 , A61K31/435 , A61K31/46 , A61K31/55 , A61P1/00 , A61P1/08 , A61P11/00 , A61P25/20 , A61P35/00 , C07D209/52 , C07D451/04 , C07D451/12 , C07D453/02 , C07D453/06
CPC分类号: A61K31/435 , A61K31/40 , A61K31/405 , A61K31/415 , A61K31/46
摘要: A method of treatment of emesis, anxiety and/or IBS in mammals, including humans, which method comprises administering an effective amount of a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof:Ar--CO--Y--Z (I)wherein Ar is a group of formula (a): ##STR1## wherein: R.sub.1 and R.sub.2 are independently selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl groups, thiol, C.sub.1-4 alkylthio; X is CH.sub.2, NR.sub.3, --O-- or --S-- wherein R.sub.3 is hydrogen, C.sub.1-4 alkyl, C.sub.3-5 alkenyl, phenyl or phenyl C.sub.1-4 alkyl; or Ar is a group of formula (b): ##STR2## wherein R.sub.4 to R.sub.7 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl, by C.sub.1-4 alkanoylamino or pyrrolyl, one of R.sub.4 to R.sub.7 being other than hydrogen;Y is --O-- or --NH--; andZ is a group of formula (c), (d) or (e): ##STR3## wherein n is 2, 3 or 4;R.sub.8 is hydrogen, C.sub.1-7 alkyl, C.sub.3-5 alkenyl or phenyl C.sub.1-4 alkyl optionally substituted by one or two halogen, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; ##STR4## wherein: p is 1, 2 or 3; andR.sub.9 is as defined above for R.sub.8 ; and with the proviso that, when Ar is of formula (b) and Y is --NH--, Z is a group of formula (d) or (e); ##STR5## wherein R.sub.10 is hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl-C.sub.1-3 alkyl; andone of the groups represented by R.sub.11, R.sub.12 and R.sub.13 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl and each of the other groups, which may be the same or different, is hydrogen or C.sub.1-6 alkyl.
-
公开(公告)号:US4845092A
公开(公告)日:1989-07-04
申请号:US145537
申请日:1988-01-19
申请人: Gareth J. Sanger , Helen E. Marr
发明人: Gareth J. Sanger , Helen E. Marr
IPC分类号: C07D209/52 , A61K31/40 , A61K31/403 , A61K31/435 , A61K31/445 , A61K31/46 , A61K31/55 , A61P1/00 , A61P25/04 , C07D451/06 , C07D451/14 , C07D453/02 , C07D453/06
CPC分类号: A61K31/46 , A61K31/435 , A61K31/445 , A61K31/55
摘要: A method of treatment of visceral pain in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:X-CO-Y-Z (I)whereinX is a group of formula (a), (b), (c), (d) or (e): ##STR1## wherein R.sub.a to R.sub.d are selected from hydrogen, halogen or hydroxy;R.sub.1 is hydrogen and R.sub.2 is hydrogen or C.sub.1-4 alkyl; orR.sub.1 and R.sub.2 together are a bond;R.sub.3 and R.sub.7 are independently hydrogen or C.sub.1-6 alkyl; andR.sub.4 together with R.sub.2 may be C.sub.2-7 polymethylene when R.sub.1 is hydrogen;either R.sub.8 is C.sub.1-6 alkoxy;R.sub.9 is hydrogen;R.sub.10 is amino or C.sub.1-7 alkanoylamino; andR.sub.11 is halo or C.sub.1-6 alkylthio; orR.sub.8 is hydrogen;R.sub.9 is halo, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;R.sub.10 is hydrogen or C.sub.1-6 alkoxy; andR.sub.11 is halo, C.sub.1-6 alkoxy or C.sub.1-6 alkyl;L is CH or N;Y is NH or O, with the proviso that Y is NH when X is (e) and R.sub.8 is C.sub.1-6 alkoxy;Z is a group of formula (f), (g) or (h): ##STR2## wherein n is 2 or 3;p and q are independently 1 to 3; andR.sub.12 and R.sub.13 is methyl or ethyl.
-
7.
公开(公告)号:US4786643A
公开(公告)日:1988-11-22
申请号:US122920
申请日:1987-11-19
申请人: Gareth J. Sanger , Wesley D. Miner
发明人: Gareth J. Sanger , Wesley D. Miner
IPC分类号: C07D451/14 , A61K31/435 , A61K31/445 , A61K31/46 , A61K31/55 , A61P1/08 , A61P9/06 , A61P25/04
CPC分类号: A61K31/55 , A61K31/445 , A61K31/46
摘要: A method of treatment of migraine, cluster headaches and trigeminal neuralgia, radiation or cytotoxic agent induced nausea and vomiting and/or cardiac arrhythmia in mammals, including humans, which method comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is C.sub.1-6 alkyl;R.sub.2 is amino or C.sub.1-7 acylamino;R.sub.3 is halo;one of R.sub.4 and R.sub.5 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-3 alkyl, which phenyl moieties may be substituted by one or more substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3 or halogen;the other of R.sub.4 and R.sub.5 is hydrogen or C.sub.1-6 alkyl;p is 0 to 2; andq is 0 to 3.
-
公开(公告)号:US5580885A
公开(公告)日:1996-12-03
申请号:US204429
申请日:1994-07-28
申请人: Francis D. King , Laramie M. Gaster , Keith R. Mulholland , Shirley K. Rahman , Paul A. Wyman , Gareth J. Sanger , Kay A. Wardle , Gordon S. Baxter , Guy A. Kennett , Alberto J. Kauman
发明人: Francis D. King , Laramie M. Gaster , Keith R. Mulholland , Shirley K. Rahman , Paul A. Wyman , Gareth J. Sanger , Kay A. Wardle , Gordon S. Baxter , Guy A. Kennett , Alberto J. Kauman
IPC分类号: A61K31/245 , A61K31/38 , A61K31/395 , A61K31/40 , A61K31/415 , A61K31/435 , A61K31/437 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4453 , A61K31/452 , A61K31/454 , A61K31/47 , A61K31/535 , A61K31/55 , A61P9/06 , A61P25/00 , A61P25/20 , A61P43/00 , C07D209/42 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D455/02 , C07D471/04
CPC分类号: C07D405/12 , A61K31/245 , A61K31/38 , A61K31/395 , A61K31/40 , A61K31/415 , A61K31/437 , A61K31/445 , A61K31/4453 , A61K31/452 , A61K31/454 , A61K31/47 , A61K31/55 , C07D209/42 , C07D409/12 , C07D413/04 , C07D413/10 , C07D455/02 , C07D471/04
摘要: The use of a compound of formula (I) or pharmaceutically acceptable salt thereof, in which X.sub.1 --(CH.sub.2).sub.x --X.sub.2 forms a 5-7 membered ring wherein: X.sub.1 is O or S; X.sub.2 is O, S, NR or NRCO wherein R is hydrogen or C.sub.1-6 alkyl; x is 1, 2 or 3; Y is O or NH; Z is sub-formula (a), (b) or (c) in the manufacture of a medicament for use in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
摘要翻译: PCT No.PCT / GB92 / 01649 Sec。 371日期:1994年7月28日 102(e)日期1994年7月28日PCT提交1992年9月9日PCT公布。 出版物WO93 / 05038 日期:1993年3月18日
(I) (a) (b) (c)使用式(I)化合物或其药学上可接受的盐,其中X1- (CH 2)x -X 2形成5-7元环,其中:X 1是O或S; X 2是O,S,NR或NRCO,其中R是氢或C 1-6烷基; x为1,2或3; Y是O或NH; Z是在制备用于治疗胃肠疾病,心血管疾病和CNS障碍的药物中的子式(a),(b)或(c)。 -
公开(公告)号:US4783478A
公开(公告)日:1988-11-08
申请号:US71424
申请日:1987-07-09
申请人: Gordon Wootton , Gareth J. Sanger
发明人: Gordon Wootton , Gareth J. Sanger
IPC分类号: C07D403/06 , A61K31/40 , A61K31/403 , A61K31/405 , A61K31/415 , A61K31/435 , A61K31/46 , A61K31/55 , A61P1/00 , A61P1/08 , A61P11/00 , A61P25/20 , A61P35/00 , C07D209/52 , C07D451/04 , C07D451/12 , C07D453/02 , C07D453/06
CPC分类号: A61K31/435 , A61K31/40 , A61K31/405 , A61K31/415 , A61K31/46
摘要: A method of treatment of emesis, anxiety and/or IBS in mammals, including humans, which method comprises administering an effective amount of a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof:Ar--CO--Y--Z (I)wherein Ar is a group of formula (a): ##STR1## wherein: R.sub.1 and R.sub.2 are independently selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl groups, thiol, C.sub.1-4 alkylthio; X is CH.sub.2, NR.sub.3, --O-- or --S-- wherein R.sub.3 is hydrogen, C.sub.1-4 alkyl, C.sub.3-5 alkenyl, phenyl or phenyl C.sub.1-4 alkyl;or Ar is a group of formula (b): ##STR2## wherein R.sub.4 to R.sub.7 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, amino optionally substituted by one or two C.sub.1-4 alkyl, by C.sub.1-4 alkanoylamino or pyrrolyl, one of R.sub.4 to R.sub.7 being other than hydrogen;Y is --O-- or --NH--; andZ is a group of formula (c), (d) or (e): ##STR3## wherein n is 2, 3 or 4;R.sub.8 is hydrogen, C.sub.1-7 alkyl, C.sub.3-5 alkenyl or phenyl C.sub.1-4 alkyl optionally substituted by one or two halogen, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; ##STR4## wherein: p is 1, 2 or 3; andR.sub.9 is as defined above for R.sub.8 ;and with the proviso that, when Ar is of formula (b) and Y is --NH--, Z is a group of formula (d) or (e); ##STR5## wherein R.sub.10 is hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl-C.sub.1-3 alkyl; andone of the group represented by R.sub.11, R.sub.12 and R.sub.13 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-C.sub.1-3 alkyl and each of the other groups, which may be the same or different, is hydrogen or C.sub.1-6 alkyl.
-
公开(公告)号:US4725603A
公开(公告)日:1988-02-16
申请号:US876724
申请日:1986-06-20
申请人: Gareth J. Sanger , Wesley D. Miner
发明人: Gareth J. Sanger , Wesley D. Miner
IPC分类号: C07D451/14 , A61K31/435 , A61K31/445 , A61K31/46 , A61K31/55 , A61P1/08 , A61P9/06 , A61P25/04 , A61K31/44
CPC分类号: A61K31/55 , A61K31/445 , A61K31/46
摘要: A method of treatment of migraine, cluster headaches and trigeminal neuralgia, radiation or cytotoxic agent induced nausea and vomiting and/or cardiac arrhythmia in mammals, including humans, which method comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is C.sub.1-6 alkyl;R.sub.2 is amino or C.sub.1-7 acylamino;R.sub.3 is halo;one of R.sub.4 and R.sub.5 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-3 alkyl, which phenyl moieties may be substituted by one or more substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3 or halogen;the other of R.sub.4 and R.sub.5 is hydrogen or C.sub.1-6 alkyl;p is 0 to 2; andq is 0 to 3.
摘要翻译: 一种治疗偏头痛,丛集性头痛和三叉神经痛,辐射或细胞毒剂的哺乳动物包括人的恶心和呕吐和/或心律失常的方法,包括给予有效量的式(I)化合物或其药学上可接受的盐 (I)其中:R 1是C 1-6烷基; R2是氨基或C1-7酰氨基; R3是卤素; R4和R5之一是氢,C1-6烷基,苯基或苯基C1-3烷基,该苯基部分可以被一个或多个选自C 1-6烷基,C 1-6烷氧基,CF 3或卤素的取代基取代; R4和R5中的另一个是氢或C 1-6烷基; p为0〜2; q为0〜3。
-
-
-
-
-
-
-
-
-